KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Consolidated Net Income (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Consolidated Net Income for 18 consecutive years, with -$92.5 million as the latest value for Q1 2026.

  • For Q1 2026, Consolidated Net Income rose 37.03% year-over-year to -$92.5 million; the TTM value through Mar 2026 reached $54.2 million, up 1922.5%, while the annual FY2025 figure was -$207000.0, 103.04% down from the prior year.
  • Consolidated Net Income hit -$92.5 million in Q1 2026 for Ionis Pharmaceuticals, down from $151.8 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $356.4 million in Q4 2024 and bottomed at -$147.4 million in Q3 2023.
  • Average Consolidated Net Income over 5 years is -$42.5 million, with a median of -$85.2 million recorded in 2023.
  • Year-over-year, Consolidated Net Income plummeted 213.58% in 2023 and then surged 3661.85% in 2024.
  • Ionis Pharmaceuticals' Consolidated Net Income stood at -$52.5 million in 2022, then soared by 80.93% to -$10.0 million in 2023, then soared by 3661.85% to $356.4 million in 2024, then crashed by 57.41% to $151.8 million in 2025, then plummeted by 160.96% to -$92.5 million in 2026.
  • According to Business Quant data, Consolidated Net Income over the past three periods came in at -$92.5 million, $151.8 million, and -$128.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.